Pulmonary Function and Chest Computed Tomography (CT) Scan Findings After Antifibrotic Treatment for COVID-19-Related Pulmonary Fibrosis

13 February 2022: Articles

Unusual setting of medical care

Jan Michael Jesse Lomanta ^A* , Milraam L. Quinto ^B , Sheen C. Urquiza ^C , Joel M. Santiaguel ^A

DOI: 10.12659/AJCR.934830

Am J Case Rep 2022; 23:e934830

Table 1. Summary of 6-Minute Walk Test, Pulmonary Function Test, and Chest CT Score Results.

	Baseline	1 month after Nintedanib treatment	6 months after Nintedanib treatment
6-minute walk distance	297 meters	434 meters	457meters
Oxygen supplementation	2 lpm	2 lpm	None
Borg dyspnea scale	7 (very severe)	4 (somewhat severe)	1 (very slight)
FEV1/FVC	0.90	0.80	0.80
FEV1	54%	64%	81%
FVC	0.49	0.62	0.75
TLC	52%	64%	81%
DLCO	28% predicted (severely reduced)	36% predicted (moderately reduced)	59% predicted (moderately reduced)
Chest CT scoring	18	16	15
^* Predicted distance=533 meters; ^** severity score: 7 or less=mild, 8–17=moderate, 18 or more=severe. FEV1 – forced expiratory volume at 1 second; FVC – forced vital capacity; TLC – total lung capacity; DLCO – diffusing capacity of the lung for carbon monoxide; LPM – liters per minute.